Drug intelligence / Profile preview

rocuronium + lidocaine

Development stage
Unknown
Lead developer
Organon
Modality
Small Molecules
Administration
Intravenous
01

Overview

Rocuronium + lidocaine is a combination of two pharmaceutical agents commonly used in anesthesia practice. Rocuronium is a non-depolarizing neuromuscular blocking agent (muscle relaxant) of the aminosteroid class, primarily used to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation. Lidocaine is an amide-type local anesthetic and antiarrhythmic agent, often administered intravenously to reduce pain on injection of other drugs (such as rocuronium or propofol), blunt hemodynamic responses to intubation, and potentially enhance the effects of neuromuscular blockers. When combined, lidocaine may improve intubating conditions by reducing pain from rocuronium injection and may slightly modify the onset or duration of neuromuscular blockade; however, evidence suggests that while lidocaine can improve patient comfort and block increases in heart rate after intubation, its effect on the pharmacodynamics of rocuronium is limited[1][3][8]. This combination does not have a unique brand name but represents concurrent use for procedural purposes.

02

Targets

Nicotinic Acetylcholine ReceptorSCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on rocuronium + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rocuronium + lidocaine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call